Blog

Neovacs signs agreement with Amega Biotech to acquire IFNa manufacturing license

Neovacs, a leader in active immunotherapies for the treatment of autoimmune diseases, announced an agreement with the Argentinean company Amega Biotech to acquire its Interferon Alpha (IFNa) manufacturing license. IFNa is a key component of Neovacs’ lead therapeutic candidate, IFNa Kinoid, which is composed of inactivated IFNa coupled with a carrier protein, keyhole limpet hemocyanin.

Miguel Sieler, CEO of Neovacs, commented: "With this agreement, the company has reinforced its ability to maintain control of its technology, quality control, manufacturing and costs, which is key to our overall growth strategy as we continue advancing the clinical development of our lead candidate IFNa Kinoid. With greater control over our Kinoid technology, we can drive optimization of manufacturing costs and more effectively support the potential commercialization of IFNa Kinoid for the treatment of lupus, a complex autoimmune disease where medical needs are urgent and unmet today.”

Amega Biotech is a leading global producer of IFNa protein and a long term supplier of Neovacs, particularly for its on-going Phase IIb study of IFNa Kinoid in Lupus. Their product is recognized by the international biotechnology and pharmaceutical industry for the quality of its technological manufacturing, which also meets all relevant international standards for GMP (Good manufacturing Practice).

                                                                                                                                                                                         -18/11/2016